As more novel ophthalmic drugs and devices become available under the CMS “pass-through”designation, practices should be proactive in embracing these products.
Patti Barkey, COE, OCS
Advertisement
Articles by Patti Barkey, COE, OCS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa
2
Q&A: Peter Kaiser explains the ongoing SOL-1 and SOL-R study of OTX-TKI
3
AAO 2025: Don’t miss presentations from our Editorial Advisory Board members
4
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA
5
.png "Optometry Times"){kind=logo}
